

# CITATION REPORT

List of articles citing

[Predictive value of PD-L1 diagnostics]

DOI: 10.1007/s00292-018-0507-x  
Der Pathologe, 2018, 39, 498-519.

**Source:** <https://exaly.com/paper-pdf/70745480/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
55	[Predictive biomarkers in bladder cancer]. <i>Der Pathologe</i> , <b>2019</b> , 40, 331-338	1	1
54	[Use of monoclonal antibodies in pathological diagnostics]. <i>Der Internist</i> , <b>2019</b> , 60, 1021-1031	0	3
53	[Predictive biomarkers in oncologic uropathology]. <i>Der Pathologe</i> , <b>2019</b> , 40, 264-275	1	1
52	PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival. <i>Pathology Research and Practice</i> , <b>2019</b> , 215, 152402	3.4	5
51	The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer. <i>Pancreas</i> , <b>2019</b> , 48, 904-912	2.6	10
50	Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 145-153.e5	3.3	10
49	Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease. <i>BMC Research Notes</i> , <b>2020</b> , 13, 139	2.3	2
48	Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate. <i>Cancers</i> , <b>2020</b> , 12,	6.6	15
47	PPAR $\gamma$ induces PD-L1 expression in MSS+ colorectal cancer cells. <i>OncolImmunology</i> , <b>2021</b> , 10, 1906500	7.2	4
46	Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. <i>Pathology</i> , <b>2021</b> , 53, 141-156	1.6	25
45	Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	6
44	Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
43	Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
42	Epstein-Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma. <i>Microorganisms</i> , <b>2021</b> , 9,	4.9	4
41	Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
40	Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
39	[Predictive diagnostics for checkpoint inhibitors]. <i>Der Pathologe</i> , <b>2021</b> , 42, 380-390	1	0

38	Comparison of PD-L1 Scores in Primary Kidney Tumors Versus Accompanying Venous Tumor Thrombi: Retrospective, Comparative, Monocentric Study in Treatment-Naive Patients. <i>Advances in Therapy</i> , <b>2021</b> , 38, 3373-3388	4.1	0
37	Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonists. <i>International Journal of Colorectal Disease</i> , <b>2021</b> , 36, 2497-2510	3	0
36	Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological Response. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 720951	5.3	1
35	The peri- and intratumoral immune cell infiltrate and PD-L1 status in invasive squamous cell carcinomas of the penis. <i>Clinical and Translational Oncology</i> , <b>2021</b> , 1	3.6	2
34	Shifting Gears in Precision Oncology-Challenges and Opportunities of Integrative Data Analysis. <i>Biomolecules</i> , <b>2021</b> , 11,	5.9	2
33	Head and neck cancer. <i>Lancet, The</i> , <b>2021</b> ,	40	36
32	PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 734.e1-734.e10	2.8	1
31	The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers. <i>Memo - Magazine of European Medical Oncology</i> , <b>2020</b> , 13, 11-26	0.3	2
30	The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma - systematic review and discussion of current therapeutic options. <i>Wspolczesna Onkologia</i> , <b>2021</b> , 25, 213-223	1	1
29	Synergies Radiotherapy-Immunotherapy in Head and Neck Cancers. A New Concept for Radiotherapy Target Volumes-"Immunological Dose Painting". <i>Medicina (Lithuania)</i> , <b>2020</b> , 57,	3.1	0
28	Pan-Cancer Biomarkers: Changing the Landscape of Molecular Testing. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2021</b> , 145, 692-698	5	3
27	[Immunohistochemistry-based predictive biomarkers for lung cancer]. <i>Der Pathologe</i> , <b>2020</b> , 41, 21-31	1	1
26	Biomarker bei HNSCC und die Rolle der Immunonkologie. <i>Tumor Diagnostik Und Therapie</i> , <b>2020</b> , 41, 517-520	5.2	0
25	Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	2
24	Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups.. <i>Immunologic Research</i> , <b>2022</b> , 70, 256	4.3	1
23	A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer.. <i>Breast Cancer</i> , <b>2022</b> , 1	3.4	0
22	Mutational and immunologic Landscape in malignant Salivary Gland Tumors harbor the potential for novel therapeutic strategies.. <i>Critical Reviews in Oncology/Hematology</i> , <b>2022</b> , 170, 103592	7	0
21	The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer-An Overview.. <i>Current Oncology</i> , <b>2021</b> , 28, 5227-5239	2.8	0

20	Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer.. <i>Molecular and Clinical Oncology</i> , <b>2022</b> , 16, 91	1.6	
19	Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood.. <i>Cancer Immunology, Immunotherapy</i> , <b>2022</b> , 1	7.4	1
18	Multiple Immunostainings with Different Epitope Retrievals-The FOLGAS Protocol.. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 23,	6.3	
17	Decision Support for Oropharyngeal Cancer Patients Based on Data-Driven Similarity Metrics for Medical Case Comparison.. <i>Diagnostics</i> , <b>2022</b> , 12,	3.8	0
16	Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen. <i>Frontiers in Immunology</i> , <b>2022</b> , 13,	8.4	
15	Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE). <i>International Journal of Surgery</i> , <b>2022</b> , 106680	7.5	1
14	Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer. <i>Nuklearmedizin - NuclearMedicine</i> ,	1.8	
13	The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition.		0
12	Frequency and Prognostic Significance of Intertumoural Heterogeneity in Multifocal Jejunoileal Neuroendocrine Tumours. <b>2022</b> , 14, 3963		
11	Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma. <b>2022</b> , 176, 13-29		0
10	Immune-Checkpoint-Inhibitor Therapy Principles and Relevance of Biomarkers for Pathologists and Oncologists. Publish Ahead of Print,		0
9	The prognostic impact of the immune microenvironment in small-cell neuroendocrine carcinoma of the uterine cervix: PD-L1 and immune cell subtypes. <b>2022</b> , 22,		0
8	Role of Surgical Pathologist for Detection of Predictive Immuno-oncological Factors in Breast Cancer. Publish Ahead of Print,		0
7	Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis. 1-11		0
6	Immunonkologie beim Mammakarzinom: neue Therapieoption für die triple-negative Patientin.		0
5	Assessing PD-L1 Expression in Different Tumor Types. <b>2023</b> , 1-21		0
4	Synergic Induction of Autophagic Cell Death in Anaplastic Thyroid Carcinoma. <b>2023</b> , 41, 405-421		0
3	CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway. <b>2023</b> , 95,		0

- 2 Adenoid cystic carcinoma of the salivary glands: a pilot study of potential therapeutic targets and characterization of the immunological tumor environment and angiogenesis. ○
- 1 Anti-PD-(L)1 therapy of non-small cell lung cancer: a summary of clinical trials and current progresses. **2023**, 9, e14566 ○